Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...

A Massachusetts man who, along with his girlfriend, defrauded Takeda Pharmaceutical Co. of $2.3 million and used the money to ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...

Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other pharma stocks. The Rising Demand for Weight-Loss Medications and GLP ...

raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full ...

Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...

A Brockton man was sentenced for defrauding a pharmaceutical company out of $2.3 million and spending the proceeds on a ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...